U.S. market Closed. Opens in 1 day 6 hours 11 minutes

QLGN | Qualigen Therapeutics, Inc. Stock Financials Income Statements Annual

(Stock Exchange: NASDAQ)
*Sign In to persist settings
Financial Year End2023-12-312022-12-312021-12-312020-12-312020-03-31
Revenue5.20M4.98M5.65M4.31M5.56M
Cost of Revenue5.21M4.30M4.33M7.19M3.98M
Gross Profit-4.50K680.80K1.32M-2.88M1.58M
Operating Expenses6.10M18.62M23.98M17.40M3.08M
Selling, General & Admin6.09M11.79M12.27M8.42M1.88M
Research & Development5.21M6.84M11.72M3.55M1.21M
Other Operating Expenses-5.21M1.12K5.45KN/A2.79K
Operating Income-11.30M-17.94M-22.66M-11.30M-1.50M
Other Expenses / Income-1.17M872.81K4.77M-7.74M711.17K
Before Tax Income-12.48M-21.30M-17.89M-20.42M-1.78M
Income Tax Expenses-4.79K-265.07K5.43K619.004.00K
Net Income-13.42M-21.03M-17.90M-20.42M-1.79M
Interest Expenses1.52M26.65KN/AN/A283.10K
Basic Shares Outstanding5.07M3.84M2.93M723.72K627.00K
Diluted Shares Outstanding5.07M3.84M2.93M723.72K627.00K
EBITDA-11.30M-13.84M-22.66M-11.16M-10.02M
EBITDA Margin-217.12%-277.74%-400.85%-259.27%-180.31%
EBIT-11.90M-21.27M-17.89M-20.42M-1.50M
EBIT Margin-228.58%-426.87%-316.46%-474.15%-27.00%
Financial Year End2023-12-312022-12-312021-12-312020-12-312020-03-31
An error has occurred. This application may no longer respond until reloaded. Reload 🗙